Animal Models in Behçet's Disease by Yildirim, Ozlem
Hindawi Publishing Corporation
Pathology Research International
Volume 2012, Article ID 273701, 8 pages
doi:10.1155/2012/273701
Review Article
AnimalModelsinBehc ¸et’sDisease
Ozlem Yildirim
Department of Ophthalmology, Faculty of Medicine, Mersin University, 33070 Mersin, Turkey
Correspondence should be addressed to Ozlem Yildirim, dryildirimoz@hotmail.com
Received 26 August 2011; Revised 3 November 2011; Accepted 4 November 2011
Academic Editor: ¨ Umit Tursen
Copyright © 2012 Ozlem Yildirim. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Behc ¸et’s disease is a chronic, recurrent, multisystemic, inﬂammatory disorder aﬀecting mainly the oral and urogenital mucosa and
the uveal tract. Although the etiology and pathogenesis of Behc ¸et’s disease are unknown, numerous etiologies have been proposed,
includingenvironmental,infectious,andimmunologicalfactors;anautoimmunebasis,characterizedbycirculatingimmunecom-
plexes and complement activation, has gained increasing acceptance. To test and understand immunopathogenesis of Behc ¸et’s dis-
ease, animal models were developed based on enviromental pollutants, bacterial and human heat shock protein derived peptides,
and virus injections. Using these animal models separately and/or concurrently allows for a more eﬀective investigation into
Behc ¸et’s disease. Animal models developed in the last 10 years aim at the development of eﬃcient and safe treatment options.
1.Introduction
Behc ¸et’s disease (BD) is a chronic, multisystemic, inﬂamma-
tory disorder and is characterizedby mucocutaneous, ocular,
arthritic, vascular, gastrointestinal, and central nervous sys-
tem involvement. The disease has a chronic course with peri-
odic exacerbations and progressive deterioration [1].
Since the dermatologist Dr. Hulusi Behc ¸et [2]c o m p r e -
hensively described this disease involving multisystemic or-
gans in 1937, the etiology of BD has still remained unclear.
Various hypotheses have been proposed centering on viral
infection, autoimmune disease, streptococcal-related anti-
gens, speciﬁc alleles of the human major histocompatibility
complex, genetic factors, and hazardous chemicals [3–7].
The history and recent developments in the immunopatho-
genesis of BD are reviewed and discussed in this paper.
2. Short History
Viral infection has long been postulated as one of the etiolo-
gic and triggering factors. Hulusi Behc ¸et proposed that the
diseasewascausedbyaspecialvirus.Althoughhewasunable
to demonstrate one, he had observed intracellular inclusion-
like forms in smears from the hypopyon of the anterior
chamber and aphthae [2]. In 1953, Sezer [8] was the ﬁrst to
isolate the virus from ocular ﬂuid and serially cultivate it in
chorioallantoic membrane of fertile eggs. He inoculated the
material from the ocular ﬂuid of patients into brains of mice.
Inoculated mice showed manifestation such as roughening
of the coat, inactivity or hyperactivity, tremor, circling, para-
lysis, encephalitis, thrombophlebitis, and swelling. Evans
et al. [9] isolated the virus from the eye and brain of a patient
who died of the disease. Mortada and Imam [10]f o u n d
inclusion bodies from scrapings of the scrotal and buccal
ulcers, as well as from the hypopyon ﬂuid. When the ﬂuid
fromthescrapingsofscrotalandbuccalulcersandhypopyon
was inoculated into the chorioallantoic membrane of 10-
day-old chick embryos and incubated for 2 days, whitish
plaques were seen. These plaques showed inclusion bodies
exactlylikethoseseeninscrapings.Theﬁltratesfromplaques
were inoculated intracerebrally into 3-week-old white Swiss
mice. Seventeen out of 21 mice died while 5 control mice
inoculated with saline remaining alive.
Eglin et al. [11] using method of in situ hybridization,
detectedRNAcomplementarytoherpessimplexvirus(HSV)
type 1 in the mononuclear cells of patients with BD. HSV
type 1 DNA was detected in the whole blood by Bonass et al.
[12] with dot blotting technique. Denman and colleagues
[13] detected HSV DNA with southern hybridization using
Eco R1 digested DNA from the peripheral blood mononu-
clear cells of patients with BD. In 1991, Studd et al. [14]d e -
tected HSV-1 DNA by polymerase chain reaction (PCR) in2 Pathology Research International
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Figure 1: Role of bacterial and human heat shock protein (HSP) 60/65 as T cell antigens in Behc ¸et’s disease. APC: antigen presenting cells.
peripheral blood leukocytes of BD patients with recurrent
oral ulcers.
Lee et al. [15] tried to detect HSV DNA in saliva of pa-
tients with BD, and to evaluate whether the presence of HSV
in saliva is associated with the presence of an intraoral ulcer,
and to investigate any possible relationships between HSV
and BD using PCR. The results from saliva showed that
almost 40% patients were positive for HSV DNA, compared
to 14% of healthy controls.
Lee and colleagues [16] investigated the relationship of
intestinal ulceration of BD and HSV. PCR results were all
positive in specimens of patients with BD. Bang et al. [17]
experimented to detect HSV DNA from ulcerative genital
tissue of patients with BD. They applied 8 cases and all show-
ed HSV bands. From these reports, we can conclude that
there is a relationship between HSV DNA and ulceration of
various epithelial tissue of BD.
3.AnimalModels Aimingto Elucidatethe
Immunopathogenesis of Behc ¸et’sDisease
Animal models are very important and necessary in most
ﬁelds of research. Many investigators have tried to develop
an animal model for use in BD. In 1979, Hori and colleagues
[4] created typical BD-like lesions in Pitman-Moor’s strain,
miniature swine treated with agricultural chemicals such
as organophosphate, organochloride, and inorganic copper.
The total number of animals used for the development of an
animal model by Hori and colleagues was 8. Though all of
the experimental animals showed BD-like symptoms after a
1-year administration of the chemicals, it is not feasible to
breed such a large group for use in other experimental de-
sign.
Heat shock protein (hsp) has also been implicated in the
pathogenesis of several human and experimentally induced
autoimmune diseases such as BD, both as target antigens and
as intracellular chaperones involved in peptide binding to
HLAantigens[18](Figure 1).Lehneretal.[19]reportedthat
uveitis could be induced in Lewis rats by 4 peptides derived
from the sequence of the mycobacterial 65kDhsp, which sti-
mulate speciﬁcally TCR γδ lymphocyte from patients with
BD and human 65kD hsp derived peptides. Lehner groups’
Lewis rats showed only single eye symptom. Patients’ symp-
toms of BD are multiple, chronic, or recurrent. If additional
symptoms were to appear in hsp derived peptide stimulated
Lewis rats, this animal model would be more useful.
Before using the ICR mouse strain, Sohn et al. tried
guinea pig and Sprague-Dawley rat models. They used sub-
cutaneous injections in back skin and the scrotum, intra-
muscular injections in the tongue, and a direct swab on the
eyeball. Using these methods, no symptoms similar to BD
appeared.Theythoughtthatthekeypointforsuccesswasthe
correct identiﬁcation of the route of infection of HSV. The
routeofHSVinfectionisanimportantfactoraﬀectingmulti-
systemic expressions of the symptoms.
In 1998, Sohn et al. [20] experimented to develop an ani-
mal model for use in BD using HSV infection which was
hypothesized to be one of the etiologic or triggering factors
in BD by Lee et al. [15, 16]. To test the HSV infection hypo-
thesis and to develop an animal model, ICR mice were ino-
culated with HSV. Using method of Hirata and colleagues
[21],theearlobesof258miceofICRstrain,aged5to6weeks,
were scratched with a needle, then inoculated with 1.0 × 106
plague forming units (pfu)/mL of HSV type 1 (KOS strain)
solution. As a control, 30 mice were inoculated in the same
site with a culture medium. Four weeks later, a second inoc-
ulation was performed using the same methods, followed
by 16 weeks of observation. The mice inoculated with HSV
manifestedchanges3to4daysaftertheﬁrstinoculation. The
signs that appeared most rapidly and commonly were partial
hair loss in the face region and erythema on the scratched
earlobe. Other common symptoms were skin ulceration of
the earlobes, scruﬀ, and genitalia and eye symptoms includ-
ing keratitis, conjunctivitis, and uveitis. Mice with relatively
severe symptoms showed poor general condition and soon
died. Some mice did not show any visible symptoms, but ap-
peared to be in poor general condition, they also died. After
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keratitis were the main symptoms. These symptoms were
generally more severe than those appearing after the initial
inoculation.Twoormoresymptomsinonemousewerecon-
sideredanindicationofaBD-likesyndrome.Aftertheinduc-
ed infection, 86 mice (33.3%) died, 77 (29.8%) showed BD-
likesymptoms,and95(36.8%)hadahealthynormalappear-
ance or a single symptom. The symptoms included skin
ulcersontheearlobe,scruﬀ,abdomen,back,orface(57.1%);
eye symptoms (39.0%); partial hair loss (33.8%); genital
ulcer (19.5%); bullae (11.7%); arthritis (5.2%); gastro-
intestinal ulcer (5.2%); tongue ulcer (3.9%). The induced
BD-like symptoms were similar to the clinical manifestations
of ulcers, uveitis, and arthritis which have been signiﬁcant in
diagnosing BD in patients. Aside from hair loss, the most
frequent symptoms aﬀecting mice were skin ulcers, eye sym-
ptoms, and genital ulcers. The frequency of these symptoms
were similar to that of patients with BD.
ThePCRwasusedtodetectHSVDNAsequencesinDNA
extracted from the lesions of mice with BD-like symptoms.
The methods were almost the same as those used in the pa-
tient experiment. HSV DNA sequences were detected in the
lesional skin and gastrointestinal track, but not in normal
healthyskinarea.Abdominalskinlesionsstainedwithhema-
toxylin and eosin showed that many inﬂammatory cells had
accumulated around the blood vessel. Vasculitis was also
common in intestinal, oral, earlobular, and genital epithelial
lesions. These ﬁndings were very similar to typical morpho-
logical changes in human BD [22]. These experiments prov-
ed that it was possible to induce BD-like symptoms such as
ulceration and vascular inﬂammation in ICR mice by inocu-
latingthemwithHSV.Forthisreason,manyresearchershave
used this animal model to understand the etiopathogenesis
of BD and eﬃciency and safety of newly developed drugs in
BD.
In 1978, Ohno and Sugiura [23] reported an association
between human leukocyte antigen (HLA) and BD in Japan.
Then, several authors have presented evidence of an HLA
association with, and HLA B51, one of the split antigens
of HLA B5, was found to be the most strongly associated
genetic marker [24–26]. To pursue the correlation between
viral infection and genetic factors in the development of the
disease, several inbred mouse strains—B10.BR, B10.RIII,
C57BL/6, C3H/He, and Balb/c—which had diﬀerent hap-
lotypes of major histocompatibility complex (MHC), were
inoculated with HSV type 1 (KOS strain) using the method
of Sohn and coworkers [27]. BD-like symptoms appeared
in B10.BR, B10.RIII, and C57BL/6 as in the case of ICR
mouse strain previously reported by authors as a BD mouse
model [20]. These mouse strains manifested single or multi-
ple symptoms. Manifestations of oral, genital, skin ulcers,
uveitis,andarthritis,thatareclinicallysigniﬁcantforthedia-
gnosisofBDinpatientsappeared.Thelesionsspontaneously
healed and recurred repeatedly. According to the revised
Japanese criteria [28], the manifestations in mice were classi-
ﬁed into major and minor symptoms. Among these symp-
toms,havingmorethantwosymptoms (including andabove
one major and one minor symptom) were diagnosed as
BD-like symptoms. The mice with a single symptom were
classiﬁed as the normal group. More than 40% of B10.BR,
B10.RIII, and C57BL/6 showed BD-like symptoms, com-
pared to 2% of C3H/He and Balb/c. Inbred mice with dif-
ferent haplotype of the H-2 region showed similar incidence
rates of BD-like symptoms except C3H/He and Balb/c
strains.Theresultsfromtheseinbredmousestrainsininduc-
tion of BD-like symptoms are more important than MHC
association.
Although viral infection has long been postulated as a
contributing factor in the etiology of BD, and viral involve-
ment has been demonstrated, viral infection alone is not
suﬃcient to explain the pathogenesis of BD. Some evidence
suggeststhat immunologic abnormalities are also important.
Sohn and coworkers [29] attempted to determine whether
inactivation of macrophages inﬂuences the development of
BD and whether related cytokines play a role in the modu-
lation of BD symptoms. As previously described, an animal
model was developed by using ICR mice [20]. HSV-1 inoc-
ulation was done twice 10 days apart, which was followed
by 16 weeks of observation. Mice with ≥1 major and 1
minor symptom were classiﬁed as having BD. Liposome-
encapsulated clodronate (lip-Cl2MDP) was injected intra-
venously in mice to inactivate their macrophages. Animals
treated with HSV combined with lip-Cl2-MDP had a lower
incidence of BD-like symptoms than did those treated with
HSV alone. These results suggest that macrophages may play
an important role in the development of this disease. Macro-
phage deletion did not seem to aﬀect mortality in 2 groups.
The suppression of the development of BD-like symptoms
was correlated with the induction of interleukin (IL-) 4
expression in mouse. When the Th2 adjuvant ovalbumin-
(OVA-) alum was injected into mice with BD-like symptoms,
their cutaneous symptoms improved. Adoptive transfer with
splenocytes from OVA-alum injected mice also resulted in
improvement. These ﬁndings suggest that up-regulated Th2
cytokine expression induced by macrophage inactivation
maybecloselyrelatedtothedevelopment,deterioration,and
improvement of BD induced by HSV.
Neutrophil activation is one of the immunopathogenesis
aspects of BD. Neutrophils have a pivotal role in innate im-
mune responses. As typical BD lesions such as pustular folli-
culitis, pathergy reactions, and hypopyon have signiﬁcant
neutrophil inﬁltrations, neutrophil functions and activation
status have been investigated [30]. There are conﬂicting re-
ports of increased, normal, or decreased basal and fMLP sti-
mulated superoxide productions, phagocytosis, chemotaxis,
and neutrophil-endothelial adhesion in BD. In HLA-trans-
genicmicpresumedmodelforBD,theonlyabnormalityseen
is increased superoxide release in response to fMLP. High
superoxide responses were also present in HLA-B51+ pa-
tients and healthy controls in the same study.
In the etiology and pathogenesis of BD, immunological
factors, an autoimmune basis, characterized by circulating
immune complexes and complement activation, has gained
increasing acceptance and signiﬁcance. Previous work de-
monstrated the presence of antibodies to guinea-pig oral
mucosal cells by immunoﬂuorescence [31]. Another work
has demonstrated oligoclonal T-cell expansion in patients
with BD, suggesting an antigen-driven immune response4 Pathology Research International
[32]. Immunisation with retinal S antigen or interphotore-
ceptorretinoidbindingprotein(IRBP)causesanexperimen-
tal autoimmune uveoretinitis that resembles some human
uveitic conditions [33, 34]. In vivo or in vitro sensitised, S
antigen or IRBP speciﬁc T cells transferred to naive animals
induce experimental autoimmune uveoretinitis [35]. On the
other hand, Yamamoto and coworkers found that patients
with BD with uveitis exhibited the highest and the most freq-
uent positive responses to S antigen and IRBP, as well as to
peptide M, a main uveitogenic site of S antigen [36]. Then,
another study showed that patients with BD without uveitis
didnotdiﬀerintheirresponsestoSantigenfromtherespon-
ses in the control group [37]. Yet, more responders to IRBP
were observed in the patients group without uveitis (35%)
than in the control group (14%), although their responses
were lower than the responses observed in patients with uve-
itis.Thepresenceoflymphocyteresponsestoretinalantigens
in patients with BD without uveitis might indicate a preclini-
cal stage of ocular involvement. Thus, these data support the
idea that autoimmunity to retinal speciﬁc antigens may play
a role in the ocular inﬂammation in BD.
Immunological responses to four T-cell and B-cell epito-
peshavebeenidentiﬁedwithinthemycobacterial65-kDahsp
in patients BD [38]. The four mycobacterial T-cell epitopes
show signiﬁcant homology with the human 60-kDa mito-
chondrial hsp [39]. Some groups have found T-cell prolifer-
ative responses to human hsp60 and peptides derived from it
[40], others have found antibodies to Yersinia derived hsp60
[41]. Lehner [42] have characterized gamma-delta T-cells
reactive against several peptides of human hsp60 in patients
with BD. In 1994, Stanford et al. [43]i n v e s t i g a t e dm y c o b a c -
terial and homologous human hsp T-cell peptide epitopes
speciﬁc for T lymphocytes in BD for their pathogenicity in
Lewis rat. The potential pathogenicity of eight peptides and
two controls was assessed by administering the peptides in
enriched Freund’s adjuvant into the footpads of male Lewis
rats. In this study, they have shown that ocular signs may be
induced in Lewis rats by injecting synthetic peptides derived
from the sequences of the mycobacterium tuberculosis 65-
kd hsp, and with greater frequency by using the homologous
human hsp peptides. Mild or moderate clinical disease in
these animals appears to be more common in the anterior
segment of the eye. But, clinical involvement of the mouth,
skin, external genitalia, joints, or the neurological system was
not observed. The peptides that are most frequently recog-
nized by T lymphocytes from patients with ocular type of
BD (136–150 and 336–351) produced the highest incidence
of disease in the experimental rats. Then, in 1998, Hu et al.
[44] showed that human 60-kDa hsp-derived peptide 336–
351, which is speciﬁc in stimulating T cell responses in BD,
induced uveitis in Lewis rats when administered orally and
nasally. The mucosal route of induction of uveitis is more
likely to mimic the clinical situation, in which hsp of oral
microorganisms, such as streptococci, may elicit immune
responses which cross-react with mucosal hsp and initiate
pathological changes [38]. Besides, the experiments to pre-
vent the development of uveitis by oral or nasal administra-
tion of peptide have failed. In addition, administration of
monoclonal antibody against CD8 or CD4 revealed that,
whereasmonoclonalantibody againstCD8enhanceduveitis,
against CD4 suppressed uveitis. Thus, CD4 cells mediate
whereas CD8 cells suppress the development of uveitis.
Based on these studies, Mor and colleagues [45] initiated
a study to seek target antigens associated with the tissues
involved that might be pathogenic in laboratory animals.
Theytestedpatientseraforthepresenceofantibodiestoanti-
gens found in lysates various tissues. They identiﬁed a subset
of patients with immune reactivity to a 37-kDa antigen pre-
sent in the skin, tongue, vagina, muscle, and heart rat tissue.
In-gel digestion and mass spectrometry revealed the antigen
to be α-tropomyosin. To test whether induction of autoim-
munity to a α-tropomyosin might be pathogenic, Lewis rats
were immunized with bovine α-tropomyosin in complete
Freund’sadjuvant(CFA).Theimmunizedratsdevelopedles-
ions in the uveal tract and skin, with features of BD. Control
rats injected with PBS/CFA emulsion did not develop uveitis
or skin inﬂammation.
4.AnimalModelsDesignedtoInvestigate
the Efﬁciency of Newly Developed Drugs
Animal models have been used for evaluating the eﬃciency
of newly developed drugs as well as investigating the disease’s
etiopathogenesis. The BD-like mouse model, developed by
Sohn et al. has been found to show immunological abnor-
malities [27, 29], and thus is a valuable tool to study the
eﬀect of various therapeutic drugs. Treatment with the anti-
viral agent aciclovir has failed to alleviate the frequency and
severity of orogenital ulceration and or other disease features
in BD [46]. Sohn and coworkers [47] administered famciclo-
vir, an antiviral compound that acts against HSV, varicella-
zoster virus, and hepatitis B virus, in the HSV-induced BD
mouse model, to demonstrate the eﬃciency of famciclovir.
Using the HSV-induced BD mouse model [20], famciclovir
was administered variously before and after inoculation of
from the day of lesion occurrence, with appropriate controls.
Ulceration of the mouth and genital skin and eye involve-
ment were monitored. In addition, spleen cytokine expres-
sion was measured by PCR. Pretreatment or concurrent
treatment with famciclovir did not attenuate the occurrence
of BD symptoms. However, administration of famciclovir
from the day of lesion occurrence was eﬀective in about 60%
of mice with single symptom and 40% of those with BD
symptoms and preventing recurrence. But recurrence rate
was higher in BD mice. Oral and genital ulcers did not recur,
contrasting with skin ulceration and eye involvement which
recurred despite administration of famciclovir. Therefore,
the overall rate of improvement in BD was lower than the
rate in cases showing only a single symptom. To determine
whetherornottheimprovementofsymptomsbyfamciclovir
correlated with the expression of cytokines, RT-PCR was
performed on the spleens of improved and relapsed mice
after administration of famciclovir. IL-2 was expressed in
relapsed mice that had areas of ulcerated skin, while it was
not expressed in the improved mice. Interferon-(IFN-) γ was
always expressed and was not related to the improvement
of ulceration. IL-4 and IL-10 were not expressed at anyPathology Research International 5
time following administration of famciclovir. These ﬁndings
suggest that famciclovir might be a candidate for controlled
clinical trials in the human form of BD.
In another study, thalidomide was administered in order
to understand the mechanism for the improvement in symp-
toms in BD-like mice [48]. Despite its inherent teratogenic
risk, thalidomide has proven to be of clinical use in a small
number of immunological disease, including BD [49]. How-
ever,themechanismofactionofthalidomideinpatientswith
BD remains poorly understood. In this study, a BD-like
mouse produced by HSV inoculation, previously published
by Sohn et al. [20] was used. ICR mice were inoculated twice
with HSV over a 10-day period. Thalidomide (100μg) was
orally administered to ten BD-like mice for ﬁve consecutive
days. Placebo was administered to ten BD-like mice in an
identical manner. Eight out of ten thalidomide-treated mice
showed improvement in skin ulceration, bullae and crusting,
and intestinal and genital symptoms. The control group,
treated with PBS instead of thalidomide, did not show any
change in their BD-like symptoms. The mice were sacriﬁced
on the 6th day, and the spleens were subjected to RT-PCR,
FACS, western blot, and immunohistochemical analysis. Tu-
mor necrosis factor-(TNF-) α, macrophage inﬂammatory
protein-(MIP-) 1α, perforin, and Fas were inﬂuenced by
thalidomide treatment. These results suggest that thalido-
mide can attenuate HSV-induced BD-like symptoms in mice
through the downregulation of TNF-α (P<0.005) and the
upregulation of MIP-1α (P<0.005), perforin (P<0.05),
and Fas receptor (P<0.1).
Beneﬁcial therapeutic eﬀects have been reported for col-
chicine, thalidomide, cyclosporin A, IFN-γ, and systemic
corticosteroidsinthetreatmentofBD.Thenucleosideanalog
gemcitabine (2 ,2 -diﬂuorodeoxycytidine, dFdC) is a new
signiﬁcant immunosuppressive agent that may be useful not
onlyingraft-versus-hostdiseasebutalsoinautoimmunedis-
eases. dFdC is a nucleoside analog aﬀecting the pyrimidine
pathway. Sohn et al. designed the study in order to examine
the eﬀects and side eﬀects of gemcitabine on skin lesions of
HSV-inducedBD-likemousemodel[50].Forthedose-escal-
ation study, healthy ICR mice were treated intraperitoneally
with dFdC over 5 consecutive days. For the eﬃcacy study,
ICR mice were inoculated with HSV as described earlier and
classiﬁed as having BD according to a revised Japanese classi-
ﬁcation [20] ,a n dt h e n1 8B Dm i c ew e r er a n d o m l ya s s i g n e d
to placebo, 0.06, or 0.12μg of dFdC/day over 5 days, applied
intraperitoneally. Serum levels of IL-4, IL-6, IL-10, IFN-
γ,a n dT N F - α were determined using enzyme-linked im-
munosorbent assay. After application of 3μgo fd F d Co v e r5
days, alanine aminotransferase increased (P = 0.032), but all
other kidney and liver parameters were unchanged. In BD-
like mice, soon after 5 days of dFdC treatment, cutaneous
manifestations ameliorated by more than 60% (P = 0.017),
depending on the dFdC dose applied but not in the control
mice. There was no signiﬁcant change in cytokine levels after
5 days of dFdC treatment compared to pretreatment levels
butonlyatrendtowardreducedIL-10underdFdCtreatment
(P = 0.135), and none of the cytokine levels correlated with
response to treatment. Moreover, dFdC shows promising
eﬀectstoimprovecutaneouslesionsintheHSV-inducedBD-
like mouse model. In this animal model, eﬀects of dFdC on
cytokine proﬁle remained inconclusive.
In recent years, other options of the treatment of BD are
biologic agents. TNF-α is a potent paracrine and endocrine
mediator of inﬂammatory and immune functions. TNF-α
overexpression has been implicated in acute and chronic
inﬂammatory diseases, such as septic shock, bowel disease,
Crohn’s disease, rheumatoid arthritis, atopic dermatitis,
psoriasis, and BD [51]. TNF-α is produced primarily in T
cells, polymorphonuclear cells (PMNs), dendritic cells, and
macrophages [52]. In macrophages, TNF-α gene expression
is induced by physical, chemical, and biologic stimuli that
include ischemia, trauma, irradiation, viruses, bacteria, tu-
mor cells, complement, and cytokines. Rapidly supplanting
antisense methods [53, 54]. RNA interference (RNAi) is a
recently discovered process that utilizes either endogenous
or exogenous, double-stranded RNAs to inhibit expression
of genes in a highly sequence speciﬁc manner. In mam-
mals, RNAi can be invoked by introducing short (19–21
nucleotide),double-strandedRNAoligonucleotides,referred
toassmallinterfering(siRNAs),orsilencingRNAmolecules,
of a sequence complementary to that of the target gene. The
siRNAs are bound by an RNA inducing silencing complex in
thecytoplasmandsilencetheexpressionofthetargetmRNA.
Therefore, RNAi oﬀers promise as a novel therapeutic device
and in addition may be used as a tool in functional genomics
studies to elucidate genes controlling disease pathways [55].
To inhibit the expression of TNF-α, Choi et al. [56] used
siRNAs to reduce over expression of TNF-α in vitro in cell
cultures and in vivo BD-like mouse model for amelioration
of chronic inﬂammation. Male ICR mice were infected with
HSV-1, as previously described [20]. TNF-α siRNA was
injected intraperitoneally twice with 1-week interval. To
compare the eﬃcacy of TNF-α siRNA versus an anti-TNF-
α antibody, Inﬂiximab, and TNF-α receptor, etanercept were
administered to symptomatic mice with inﬂamed tissue,
which were subsequently observed for 2 weeks. Inﬂixi-
mab, at 150μg/mouse (5mg/kg), was intravenously injected
onlyonce.Etanercept(25μg/mouse,50mg/60kg)wasinject-
edsubcutaneouslytwiceperweek.OtherBDmiceweretreat-
ed with scrambled siRNA or were untreated as negative con-
trols. Intraperitoneal delivery of TNF-α siRNA eﬀectively
decreased BD symptoms in 18 of 32 cases (56.3%). Scram-
bled siRNA treatment decreased BD symptoms in 2 of 19
cases (10.5%). Inﬂiximab was eﬀective in 11 of 27 cases
(40.7%) and Etanercept was also eﬀective in 9 of 25 cases
(36.0%)attheendofthesecondweekaftertreatment.TNF-α
siRNA reduced serum levels of TNF-α (1.57 ± 0.43pg/mL),
comparedtolevelsinmicenotinjected(84.02±24.59pg/mL)
(P<0.01) or scramble injected (118.89 ± 20.08pg/mL)
(P<0.01). A signiﬁcant reduction in TNF-α level was
observed as early as 24h after treatment, and the level did
notrecoveruntil2weeksaftertreatment,thusdemonstrating
an immediate, potent, and lasting biologic eﬀect of siRNA
treatment. After single injection of TNF-α siRNA, improve-
ment of BD symptoms showed at 9 ± 7th day on average,
contrary, in inﬂiximab-injected group, improvement was
apparent at 15 ± 4th day after injection (P<0.05).6 Pathology Research International
Choi et al. [56] show that siRNA can be employed to
inhibit cytokine gene expression in an in vivo disease mouse
model. This inhibition may, therefore, be attributed to the
improvement of inﬂammatory symptoms.
TNF-α plays a central role in a variety of inﬂammatory
responses [57]. TNF-α and adhesion molecules have been
shown tobe upregulatedin BD patients [58, 59].In addition,
downregulation of TNF-α using anti- TNF-α antibody (in-
ﬂiximab) was found to suppress various BD symptoms in-
cluding sight-threatening panuveitis [60] and intestinal
ulcers in patients [61]a n dm i c e[ 62]. Another TNF-α block-
er, etanercept, is also known to be an eﬀective therapeutic
agent for BD patients [62]a n dm i c e[ 56]. To test for possi-
ble anti- TNF-α and anti-inﬂammatory activities, Choi et al.
[63] administered synthesized pyridine compound deriva-
tives(SK94,SK126)fromanaturalleadsourcetomice.Lipo-
polysaccharide-(LPS-) induced TNF-α production was ana-
lyzed in the endothelial cells, Raw 264.7 cells, and serum of
normal mice after treatment with SK compounds. ICR mice
were inoculated with HSV as described earlier and classiﬁed
as having BD according to a revised Japanese classiﬁcation
[20]. SK compounds (1mg) or thalidomide (50μg) were
orally administered to ﬁve to ten BD-like mice for ﬁve con-
secutive days. Placebo was administered to ten BD mice in
an identical manner. The results of the present study that
pyridinecompoundderivativescandownregulatetheexpres-
sion of TNF-α and adhesion molecules in normal mice. Fur-
thermore,thesecompounddownregulatedTNF-αandadhe-
sion molecules in BD mice and ameliorated the symptoms.
Orally administered SK compounds were found to be abel
to eﬀectively downregulate the serum level of TNF-α in LPS
treated Balb/c mice and BD mice. Additionaly, SK126 more
eﬃciently downregulated the serum level of TNF-α,s o l u b l e
intercellular adhesion molecule-1 (sICAM-1), and soluble E-
selectin when compared to thalidomide in BD mice. SK126
and SK94 more eﬃciently downregulated sICAM-1, soluble
vascular cell adhesion molecule-1 (sVCAM-1), and soluble
E-selectin when compared to thalidomide in the sera of BD
mice and it downregulated soluble E-selectin when com-
pared to the thalidomide treated group in the spleen tissues
of BD mice. SK126 and SK94 decreased monocyte chemo-
tactic protein-1 (MCP-1) in the spleen tissues of BD mice.
The change in the severity score of SK94-treated BD mice
was similar to that of the thalidomide treated-group. The
decreasing inclination of severity score was steeper in the
SK126-treated group than the thalidomide-treated group,
which demonstrates that SK126 more eﬀectively improves
BD symptoms than thalidomide. Overall, SK126 is more
eﬀective and safer than thalidomide and more convenient
than inﬂiximab or etanercept as a treatment for BD. The
downregulated cell adhesion molecules and TNF-α were
correlated with the amelioration of BD symptoms in mice.
These ﬁndings suggest that SK compounds can be used as
therapeutic agents to reduce the levels of TNF-α and adhe-
sion molecules during the treatment of inﬂammatory dis-
ease, especially through oral administration.
In conclusion, although many human and animal studies
have been made to clarify etiology and pathogenesis of BD
since the disease was ﬁrst described in 1937, the disease’s
etiopathogenesis is still controversial. Animal models devel-
oped so far has been insuﬃcient to describe both the clinical
aspects and etiopathogenesis of the disease. An ideal animal
model has not been developed yet. Therefore patient reports
issued in the literature related to BD provide more valuable
informationcomparedtoexperimentalstudies.Besidesthese
animal models may helped to determine the disease’s eﬃ-
cient and safe treatment alternatives. Better characterisation
ofpathogenic immune cellsubsets, systematicand localanti-
gens, and abnormal cell-activation mechanisms may help in
the future to develop more speciﬁc and less toxic immu-
notherapeutic approaches to the still unsatisfactory treated
BD.
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